Free Trial
NASDAQ:ONVO

Organovo 7/13/2023 Earnings Report

Organovo EPS Results

Actual EPS
-$10.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Organovo Revenue Results

Actual Revenue
$0.16 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Organovo Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Organovo's next earnings date is estimated for Friday, May 30, 2025, based on past reporting schedules.

Conference Call Resources

Organovo Earnings Headlines

Organovo (NASDAQ:ONVO) Now Covered by StockNews.com
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Two new option listings and one option delisting on April 24th
See More Organovo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Organovo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organovo and other key companies, straight to your email.

About Organovo

Organovo (NASDAQ:ONVO), a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

View Organovo Profile

More Earnings Resources from MarketBeat